JP2021521128A5 - - Google Patents
Info
- Publication number
- JP2021521128A5 JP2021521128A5 JP2020555164A JP2020555164A JP2021521128A5 JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5 JP 2020555164 A JP2020555164 A JP 2020555164A JP 2020555164 A JP2020555164 A JP 2020555164A JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- heterocyclyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659068P | 2018-04-17 | 2018-04-17 | |
| US62/659,068 | 2018-04-17 | ||
| US201862746843P | 2018-10-17 | 2018-10-17 | |
| US62/746,843 | 2018-10-17 | ||
| PCT/US2019/027992 WO2019204523A1 (en) | 2018-04-17 | 2019-04-17 | Bicyclic carboxamides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521128A JP2021521128A (ja) | 2021-08-26 |
| JP2021521128A5 true JP2021521128A5 (cg-RX-API-DMAC7.html) | 2022-04-11 |
| JP7361713B2 JP7361713B2 (ja) | 2023-10-16 |
Family
ID=66625250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555164A Active JP7361713B2 (ja) | 2018-04-17 | 2019-04-17 | 二環式カルボキサミドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10968201B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3781550B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7361713B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102815312B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112313208B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019255717B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3096894A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3781550T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3010282T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL277963B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020010879A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202010153WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019204523A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018195123A1 (en) | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| CN112313208B (zh) | 2018-04-17 | 2024-04-19 | 泰普斯特医疗公司 | 双环羧酰胺及其使用方法 |
| WO2022257960A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的双环化合物 |
| CN115448882A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| CN114085167A (zh) * | 2021-12-13 | 2022-02-25 | 华中药业股份有限公司 | 一种杂质ts-3a的制备方法 |
| WO2024102968A1 (en) * | 2022-11-10 | 2024-05-16 | Tempest Therapeutics, Inc. | Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) |
| CN118164967A (zh) * | 2022-12-08 | 2024-06-11 | 武汉人福创新药物研发中心有限公司 | 一种ep2、ep4受体拮抗剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP2007023028A (ja) * | 2005-06-16 | 2007-02-01 | Ono Pharmaceut Co Ltd | 内耳疾患治療剤 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2654811A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| ES2518919T3 (es) | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US8934426B2 (en) | 2009-04-21 | 2015-01-13 | Apple Inc. | Method and apparatus for determining channel quality index in multiple user-MIMO communication networks |
| WO2010121382A1 (en) | 2009-04-21 | 2010-10-28 | Merck Frosst Canada Ltd. | Process for making indole cyclopropyl amide derivatives |
| WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| CN103167875A (zh) * | 2010-08-17 | 2013-06-19 | 阿勒根公司 | 用于治疗角膜浑浊的ep2或ep4激动剂 |
| EP2760862B1 (en) * | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105451737B (zh) | 2013-05-23 | 2018-04-10 | 拜耳医药股份有限公司 | 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法 |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
| AU2016370779B2 (en) | 2015-12-17 | 2019-07-25 | Astex Therapeutics Limited | Quinoline-3-carboxamides as H-PGDS inhibitors |
| TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| MX385428B (es) | 2016-07-07 | 2025-03-04 | Ono Pharmaceutical Co | Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario. |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| WO2018195123A1 (en) * | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| CN112313208B (zh) | 2018-04-17 | 2024-04-19 | 泰普斯特医疗公司 | 双环羧酰胺及其使用方法 |
| CN115448882A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| US20250179017A1 (en) * | 2022-02-24 | 2025-06-05 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Carboxamide compounds as pge2 receptor antagonists |
-
2019
- 2019-04-17 CN CN201980040841.6A patent/CN112313208B/zh active Active
- 2019-04-17 WO PCT/US2019/027992 patent/WO2019204523A1/en not_active Ceased
- 2019-04-17 JP JP2020555164A patent/JP7361713B2/ja active Active
- 2019-04-17 SG SG11202010153WA patent/SG11202010153WA/en unknown
- 2019-04-17 CA CA3096894A patent/CA3096894A1/en active Pending
- 2019-04-17 MX MX2020010879A patent/MX2020010879A/es unknown
- 2019-04-17 IL IL277963A patent/IL277963B2/en unknown
- 2019-04-17 ES ES19725441T patent/ES3010282T3/es active Active
- 2019-04-17 DK DK19725441.0T patent/DK3781550T3/da active
- 2019-04-17 US US16/387,294 patent/US10968201B2/en active Active
- 2019-04-17 EP EP19725441.0A patent/EP3781550B1/en active Active
- 2019-04-17 KR KR1020207032916A patent/KR102815312B1/ko active Active
- 2019-04-17 AU AU2019255717A patent/AU2019255717B2/en active Active
-
2020
- 2020-10-14 US US17/070,554 patent/US11472789B2/en active Active
-
2022
- 2022-06-23 US US17/847,811 patent/US11795156B2/en active Active
-
2023
- 2023-02-28 AU AU2023201228A patent/AU2023201228A1/en not_active Abandoned
- 2023-09-14 US US18/467,022 patent/US12215093B2/en active Active
-
2024
- 2024-12-19 US US18/988,376 patent/US20250353829A1/en active Pending